CD8A and neoplasm: In vitro-generated DC or in vivo DC-targeting therapeutic vaccines may be designed in a manner that effectively promotes the induction of clinically-relevant Type-1 antitumor CD8+ T cells in a manner that does not require the participation of CD4+ Th cells that are likely functionally sub-optimal or inappropriately skewed (e.g., induced Treg) in the tumor-bearing host.